KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Non-Current Debt (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Non-Current Debt for 17 consecutive years, with $9.9 billion as the latest value for Q4 2025.

  • Quarterly Non-Current Debt fell 21.62% to $9.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.9 billion through Dec 2025, down 21.62% year-over-year, with the annual reading at $9.9 billion for FY2025, 21.62% down from the prior year.
  • Non-Current Debt hit $9.9 billion in Q4 2025 for Abbott Laboratories, down from $11.6 billion in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $17.5 billion in Q2 2021 to a low of $9.9 billion in Q4 2025.
  • Historically, Non-Current Debt has averaged $14.5 billion across 5 years, with a median of $14.5 billion in 2022.
  • Biggest five-year swings in Non-Current Debt: increased 4.08% in 2021 and later decreased 21.62% in 2025.
  • Year by year, Non-Current Debt stood at $17.3 billion in 2021, then dropped by 16.04% to $14.5 billion in 2022, then dropped by 6.36% to $13.6 billion in 2023, then dropped by 7.16% to $12.6 billion in 2024, then fell by 21.62% to $9.9 billion in 2025.
  • Business Quant data shows Non-Current Debt for ABT at $9.9 billion in Q4 2025, $11.6 billion in Q3 2025, and $12.9 billion in Q2 2025.